Nervgen Pharma Corp Stock Today
| NGEN Stock | CAD 2.87 0.08 2.87% |
Performance3 of 100
| Odds Of DistressOver 84
|
NervGen Pharma is selling for under 2.87 as of the 2nd of December 2024; that is 2.87% increase since the beginning of the trading day. The stock's lowest day price was 2.74. NervGen Pharma has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for NervGen Pharma Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of November 2024 and ending today, the 2nd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. The company was incorporated in 2017 and is based in Vancouver, Canada. The company has 70.31 M outstanding shares of which 199.54 K shares are now shorted by private and institutional investors with about 4.77 days to cover all short positions. More on NervGen Pharma Corp
Moving against NervGen Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NervGen Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. NervGen Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding NervGen Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO | Michael Kelly | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
NervGen Pharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to NervGen Pharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsNervGen Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NervGen Pharma's financial leverage. It provides some insight into what part of NervGen Pharma's total assets is financed by creditors.
| |||||
NervGen Pharma Corp (NGEN) is traded on TSX Venture Exchange in Canada and employs 7 people. NervGen Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 201.78 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate NervGen Pharma's market, we take the total number of its shares issued and multiply it by NervGen Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. NervGen Pharma Corp operates under Biotechnology sector and is part of Health Care industry. The entity has 70.31 M outstanding shares of which 199.54 K shares are now shorted by private and institutional investors with about 4.77 days to cover all short positions.
NervGen Pharma Corp has accumulated about 8.27 M in cash with (11.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3.
Check NervGen Pharma Probability Of Bankruptcy
Ownership AllocationNervGen Pharma Corp maintains a total of 70.31 Million outstanding shares. NervGen Pharma Corp holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check NervGen Ownership Details
NervGen Pharma Corp Risk Profiles
Although NervGen Pharma's alpha and beta are two of the key measurements used to evaluate NervGen Pharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.24 | |||
| Semi Deviation | 4.41 | |||
| Standard Deviation | 4.66 | |||
| Variance | 21.76 |
NervGen Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in NervGen Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Forecasting Now
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum |
| All Next | Launch Module |
NervGen Pharma Corporate Management
Elected by the shareholders, the NervGen Pharma's board of directors comprises two types of representatives: NervGen Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NervGen. The board's role is to monitor NervGen Pharma's management team and ensure that shareholders' interests are well served. NervGen Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NervGen Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian McAlister | CoFounder Advisor | Profile | |
| Harold DMD | CoFounder Director | Profile | |
| Elizabeth BSc | Senior Management | Profile | |
| Adam MD | Interim Director | Profile | |
| Charles DSc | Senior Operations | Profile |
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.